These Analysts Revise Their Forecasts On Nkarta After Q4 Results
Portfolio Pulse from Avi Kapoor
Nkarta, Inc. (NASDAQ:NKTX) reported a Q4 loss of 57 cents per share, beating market expectations by 2 cents. The company's CEO highlighted the potential of their CD19-directed cell therapy, NKX019, for treating severe autoimmune diseases. Despite the positive outlook, Nkarta's shares fell 5.4% in pre-market trading. Analysts from Raymond James, HC Wainwright & Co., and Needham have revised their price targets and ratings for NKTX following the earnings announcement.
March 22, 2024 | 12:17 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Nkarta reported a Q4 loss better than expected and received mixed analyst ratings and price target adjustments post-earnings.
Despite beating Q4 loss expectations, Nkarta's shares fell 5.4% in pre-market trading, indicating a negative short-term impact. The mixed analyst ratings and price target adjustments reflect uncertainty and varied expectations about the company's future performance, particularly concerning the potential of NKX019 therapy. The overall negative market reaction and analyst adjustments suggest a short-term bearish outlook for NKTX.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100